Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.

There was a significantly superior result for acute emesis in the two groups who received triple therapy on day 1 (93% and 94% for complete control of emesis vs 67% p < 0.001) and in the delayed phase those groups receiving aprepitant were significantly better (82% and 78% vs 33%, p < 0.001) although the difference between just day 1 aprepitant and daily dosing for 5 days did not reach statistical significance.

also in 111,027 other papers